SEC Form 4 · accession 0001104659-15-068867
KYTHERA BIOPHARMACEUTICALS INC · KYTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
F Michael Ball
Director
Period of report
Oct 1, 2015
Accepted (ET)
Oct 2, 2015 · 2:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001436304
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $41.95 | Oct 1, 2015 | D | 18,000 | D | — | Sep 17, 2023 | Common Stock | 18,000 | 0 | D |
| Stock Option (right to buy)F1 | $33.26 | Oct 1, 2015 | D | 8,400 | D | — | Jun 5, 2024 | Common Stock | 8,400 | 0 | D |
| Stock Option (right to buy)F1 | $53.26 | Oct 1, 2015 | D | 11,591 | D | — | Jun 2, 2025 | Common Stock | 11,591 | 0 | D |
Explanation of responses
- F1Disposed of pursuant to the Amended and Restated Agreement and Plan of Merger dated as of August 4, 2015, by and among Allergan plc (formerly known as Actavis plc) ("Allergan"), Keto Merger Sub, Inc. (a wholly owned subsidiary of Allergan) and Issuer, whereby option to purchase common stock was canceled and paid in cash assuming a stock price of $75.00.